> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/pharmacokinetics-and-metabolism.md). # Pharmacokinetics & Metabolism ## Pharmacokinetics & Metabolism ### Absorption from food Apigenin is consumed from food mainly as glycosides. Before absorption, gut enzymes — including epithelial `β-glucosidases` in the small intestine and microbial enzymes in the colon — must cleave the sugar and release free aglycone. That conversion varies between individuals and depends partly on gut microbiome composition. Free apigenin is lipophilic and a weak acid. It is better absorbed in low-pH environments, especially in the stomach and upper small intestine. It can be absorbed across the full gastrointestinal tract, but appears to absorb most efficiently at the upper end. ### Bioavailability Calculated relative oral bioavailability is about 30%, which is low by small-molecule drug standards. After oral dosing, peak plasma concentration is usually reached within 0.5 to 2.5 hours, with significant inter-study and inter-individual variability. Average elimination half-life is about 2.52 hours, with a reported range of roughly 1.8 to 4.2 hours. Systemic exposure is therefore relatively short-lived. With regular dosing, steady state would be expected within roughly 12 hours. ### Metabolism After absorption, apigenin undergoes phase II metabolism in the gut and liver, producing mainly glucuronide and sulphate conjugates. These conjugates can undergo enterohepatic recirculation. That prolongs gastrointestinal presence, but reduces net systemic levels of free apigenin. ### Tissue distribution Apigenin’s `logP` value of about `2.84` means it is lipophilic enough to cross cell membranes readily, including the blood-brain barrier. Human tissue-distribution data remain limited. Animal data suggest reasonable tissue uptake. ### Transporters Apigenin inhibits ABC drug-efflux transporters, including `P-glycoprotein` and `BCRP`, in intestinal epithelial models. That may raise intracellular concentrations of co-administered drugs and adds another interaction layer beyond CYP enzymes. For practical implications, see [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/safety-and-interactions.md) and [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/dosing-and-timing.md). ### Microbiome dependence Gut microbiota can further degrade apigenin and its metabolites into smaller phenolic compounds. Microbiome diversity and gut health influence the completeness of glycoside conversion to active aglycone. That contributes to the high inter-individual variability seen with food-derived apigenin. Liposomal formulations reduce reliance on that step. ### Main translational bottleneck The central problem is poor and variable oral bioavailability combined with short half-life and extensive first-pass metabolism. Achieving tissue concentrations that match preclinical anticancer activity is not reliably possible through normal dietary intake or conventional standard supplementation alone. Estimates suggest that the roughly `1–5 µM` in vitro activity range would require intake far above usual food exposure. That gap is why enhanced-delivery systems have become such a central part of the apigenin discussion. For formulation context, see [Liposomal Encapsulation of Anti-cancer Compounds](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds.md). ### References * Chmielewska M, et al. [Does Oral Apigenin Have Real Potential for a Therapeutic Effect in Cancer?](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full) * Liang Y, et al. [A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota](https://pmc.ncbi.nlm.nih.gov/articles/PMC6817918/) * Xu M, et al. [Absorption, distribution, metabolism and excretion of apigenin](https://www.sciencedirect.com/science/article/abs/pii/S0891584922001538) * Hou M, et al. [Recent advancement in bioeffect, metabolism, stability, and delivery systems of apigenin](https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1221227/full) --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/pharmacokinetics-and-metabolism.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.